213 related articles for article (PubMed ID: 29797251)
1. Deep Profiling of the Immune System of Multiple Myeloma Patients Using Cytometry by Time-of-Flight (CyTOF).
Smets T; Stevenaert F; Adams HC; Vanhoof G
Methods Mol Biol; 2018; 1792():47-54. PubMed ID: 29797251
[TBL] [Abstract][Full Text] [Related]
2. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
[TBL] [Abstract][Full Text] [Related]
3. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
Eveillard M; Rustad E; Roshal M; Zhang Y; Ciardiello A; Korde N; Hultcrantz M; Lu S; Shah U; Hassoun H; Smith E; Lesokhin A; Mailankody S; Landgren O; Thoren K
Br J Haematol; 2020 Jun; 189(5):904-907. PubMed ID: 32026474
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotyping by Mass Cytometry.
Behbehani GK
Methods Mol Biol; 2019; 2032():31-51. PubMed ID: 31522411
[TBL] [Abstract][Full Text] [Related]
5. Mass cytometry analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma.
Hansmann L; Blum L; Ju CH; Liedtke M; Robinson WH; Davis MM
Cancer Immunol Res; 2015 Jun; 3(6):650-60. PubMed ID: 25711758
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric DNA quantification in immunophenotyped cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood stem cell harvests and bone marrow after therapy.
Nowak R; Oelschlägel U; Range U; Bergmann S; Bornhäuser M; Hölig C; Schuler U; Krebs U; Günther H; Kroschinsky F; Ehninger G
Bone Marrow Transplant; 1999 May; 23(9):895-900. PubMed ID: 10338044
[TBL] [Abstract][Full Text] [Related]
7. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
Foureau D; Bhutani M; Guo F; Rigby K; Leonidas M; Tjaden E; Fox A; Atrash S; Paul B; Voorhees PM; Usmani SZ
Cancer Med; 2021 Oct; 10(20):6933-6936. PubMed ID: 34494717
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.
Baughn LB; Sachs Z; Noble-Orcutt KE; Mitra A; Van Ness BG; Linden MA
Leuk Lymphoma; 2017 Aug; 58(8):1931-1940. PubMed ID: 27981867
[TBL] [Abstract][Full Text] [Related]
9. Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells.
Vora AA; Mondala PK; Costello C; MacLeod AR; Crews LA
STAR Protoc; 2021 Jun; 2(2):100565. PubMed ID: 34136833
[TBL] [Abstract][Full Text] [Related]
10. [Recent development on flow cytometric immunophenotyping study in multiple myeloma --- review].
Gao X; Chen LJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):1083-6. PubMed ID: 21867649
[TBL] [Abstract][Full Text] [Related]
11. [Immunophenotypic characteristics of multiple myeloma cells].
Li JL; Liu YR; Chang Y; Fu JY; Chen SS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Jun; 10(3):226-8. PubMed ID: 12513791
[TBL] [Abstract][Full Text] [Related]
12. Mass cytometry: a highly multiplexed single-cell technology for advancing drug development.
Atkuri KR; Stevens JC; Neubert H
Drug Metab Dispos; 2015 Feb; 43(2):227-33. PubMed ID: 25349123
[TBL] [Abstract][Full Text] [Related]
13. A streamlined whole blood CyTOF workflow defines a circulating immune cell signature of COVID-19.
Geanon D; Lee B; Gonzalez-Kozlova E; Kelly G; Handler D; Upadhyaya B; Leech J; De Real RM; Herbinet M; Magen A; Del Valle D; Charney A; Kim-Schulze S; Gnjatic S; Merad M; Rahman AH
Cytometry A; 2021 May; 99(5):446-461. PubMed ID: 33496367
[TBL] [Abstract][Full Text] [Related]
14. Broad Immune Monitoring and Profiling of T Cell Subsets with Mass Cytometry.
Brodie TM; Tosevski V
Methods Mol Biol; 2018; 1745():67-82. PubMed ID: 29476463
[TBL] [Abstract][Full Text] [Related]
15. Cytometry of Mass for Murine Immunoprofiling.
Chandra V; McAllister F; Burks JK
Methods Mol Biol; 2022; 2435():129-137. PubMed ID: 34993943
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T-Cell Phenotyping Using CyTOF.
Barcenilla H; Pihl M; Sjögren F; Magnusson L; Casas R
Methods Mol Biol; 2023; 2559():231-242. PubMed ID: 36180636
[TBL] [Abstract][Full Text] [Related]
17. [Research advances of multiple myeloma immunophenotyping].
Pang Y; Li L; Kuang LP; Xiao Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1518-22. PubMed ID: 22169316
[TBL] [Abstract][Full Text] [Related]
18. Quantification of bone-marrow plasma cell levels using various International Myeloma Working Group response criteria in patients with multiple myeloma.
Narita K; Kobayashi H; Abe Y; Kitadate H; Takeuchi M; Matsue K
Int J Hematol; 2018 Oct; 108(4):371-374. PubMed ID: 29978432
[TBL] [Abstract][Full Text] [Related]
19. Feasibility study: phosphospecific flow cytometry enabling rapid functional analysis of bone marrow samples from patients with multiple myeloma.
Simard C; Cloutier M; Néron S
Cytometry B Clin Cytom; 2014 Mar; 86(2):139-44. PubMed ID: 24243860
[TBL] [Abstract][Full Text] [Related]
20. [Change of adhesion molecule expression on CD34(+) cells from bone marrow and peripheral blood during mobilization with combination of chemotherapy and G-CSF].
Da WM; Zhang M; Zhang BL; Jin HJ; Yu L; Han XP; Jing Y; Zhao Y; Wu XX; Huang WR; Wang QS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Jun; 10(3):240-2. PubMed ID: 12513794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
